Mumbai, August 20, 2014 – Drugmaker Cipla registered a profit after tax at Rs.295 crore during the three months ended June 30, 2014. Its profit after tax in the period last year was Rs.485 crore. The company said its performance was not comparable in the two quarters, as this year’s figures included results of Cipla’s subsidiaries from the date they had become a subsidiary of the company.
The company’s net sales in the period under review stood at Rs.2,647 crore, as compared to Rs.2331 crore in the same period last year. Cipla’s domestic sales stood at Rs.1,289 crore in the quarter, as compared to Rs.1102 crore last year. The growth was on the back of sales in the respiratory, anti-infective and cardiac segments, it said.
Export of finished medicine forms grew to Rs.1218 crore during Q1 FY1415 from Rs.1081 crore in the same period last year. The company’s export of active pharmaceutical ingredients marginally declined to Rs.140 crore during the quarter under review, from Rs.148 crore last year. Business Line
